Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre <i>et al</i>.

Cheng, Chao; Zhang, Fangjie

Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al.

Cheng, Chao; Zhang, Fangjie.

Cheng C; Department of Orthopaedics, Yiyang Central Hospital, Clinical Medical Technology Demonstration Base for Minimally Invasive and Digital Orthopaedics in Hunan Province, Yiyang, China.
Zhang F; Department of Emergency Medicine, Xiangya Hospital, Central South University, Changsha, China zhangfj11@163.com.

Ann Rheum Dis ; 81(10): e196, 2022 10.

Article in English | MEDLINE | ID: covidwho-724186

Subject(s)

COVID-19 Drug Treatment; Interleukin-6; Antibodies, Monoclonal, Humanized; Cohort Studies; Humans

Keywords

cytokines; epidemiology; inflammation

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2020-218616

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google